Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 129 publications
Perioperative Durvalumab for Resectable Non-Small Cell Lung Cancer: Updated Outcomes From the Phase III AEGEAN Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 28, 2026
Alirocumab Plus Cemiplimab in Immunorefractory NSCLC: A Single Arm Phase 2 Study.
Journal: Research square
Published: July 03, 2026
CLO26-092: Real-World Use of Eflapegrastim in 14-Day Chemotherapy Cycles/Dose-Dense Regimens.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: April 30, 2026
Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.
Journal: Future oncology (London, England)
Published: April 06, 2026
CLO26-092: Real-World Use of Eflapegrastim in 14-Day Chemotherapy Cycles/Dose-Dense Regimens.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: March 30, 2026
Corrigendum to "A review of relative dose intensity and survival in patients with metastatic solid tumors" [Crit. Rev. Oncol. Hematol. 93 (2015) 203-210].
Journal: Critical reviews in oncology/hematology
Published: January 31, 2026
Functional Outcomes and Quality of Life for Patients With Cachexia and Solid Tumour Cancers: Findings of a Systematic Literature Review.
Journal: Journal of cachexia, sarcopenia and muscle
Published: September 22, 2025
A Two-Stage Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Ec-18 in Altering the Severity and Course of Oral Mucositis Secondary to Chemoradiation Therapy for Squamous Cell Cancers of the Head and Neck.
Journal: Cancers
Published: March 30, 2025
Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.
Journal: Journal for immunotherapy of cancer
Published: December 29, 2024
Ponsegromab for the Treatment of Cancer Cachexia.
Journal: The New England journal of medicine
Published: September 16, 2024
Last Updated: 09/26/2026